Partikula Appoints Leading Cancer Metabolism Experts to Advisory Board; Extends Its Work On Its Multiple Checkpoint Inhibitors; Adds Seasoned Technical Development Professional to the Management Team

The addition of Matthew Vander Heiden, MD, PhD and Joshua Rabinowitz, MD, PhD bring world-class cell metabolism expertise to the Partikula Scientific Advisory Board Partikula continues to strengthen its management team as J. Michael Ramstack PhD joins the company as Vice President of Technical Operations October 13, 2016 08:00 AM Eastern Daylight Time SUNRISE, Fla.–(BUSINESS WIRE)–Partikula LLC, a late stage preclinical biotechnology company, today announced the addition of Dr. Matthew Vander Heiden and Dr. Joshua Rabinowitz to the company’s Scientific Advisory Board. “Matt and Josh bring to our team world-class expertise in the areas of cancer and cell metabolism that is second to none. Their scientific and clinical knowledge will compliment the therapeutic development work our scientists have been doing utilizing our mitochondria-targeting chemistries to modulate cancer metabolism and destroy tumors. We are very excited to have them on board and look forward to working together to bring novel and important medicines to patients,” said David Kolb, CEO of Partikula. Dr. Vander Heiden added, “The early results generated by the Partikula team are exciting. Their mitochondria-targeting chemistries seem to have afforded them the opportunity to access some interesting targets which I believe could have significant impact in the development of novel cancer therapies.” Dr. Vander Heiden is an Associate Professor at the Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, as well as an Instructor of Medicine, Dana Farber Cancer Institute and Harvard Medical School. Dr. Vander Heiden is also an Institute Member of Broad Institute of MIT and Harvard. Dr. Vander Heiden is a Member of Scientific Advisory Board at Aeglea Biotherapeutics...

Partikula Reports Positive Results From A Multi-Checkpoint Protein Inhibition Study Of Its First-In-Class Precision Tumor Microenvironment Modifiers (TMEM™)

SUNRISE, Fla.–(BUSINESS WIRE)–Partikula LLC, a preclinical-stage biotechnology company, today announced results from a study designed to assess the ability of its first-in-class compound, KULA101 to modify the tumor microenvironment and thereby increase immunological activation against cancer cells. The study found that treatment with KULA101 was able to increase the percent of CD4+ and CD8+ T-cells in tumors relative to a vehicle treatment group in a syngeneic mouse model of breast cancer. In the same study, treatment with KULA101 lowered the expression of multiple checkpoint proteins on CD4+ and CD8+ T-cells relative to vehicle treated tumors, re-activating these tumor-bound immune cells. Specifically KULA101 lowered the expression of PD-1, CTLA-4, Lag-3 and Tim-3, with median decreases of between 37% and 80%. KULA101 is designed to selectively inhibit glycolysis in cancer cells while limiting its effect on other cell types in the tumor microenvironment, including tumor-infiltrating leukocytes. KULA101 is the first of the company’s Precision Tumor Microenvironment Modifiers (TMEM™) discovered via its advanced chemistry platform. Further IND-enabling studies are ongoing for KULA101 along with additional studies being conducted on other TMEM™ therapies. “Immune checkpoint inhibitors such as Opdivo™, Keytruda™ and Yervoy™ have proven to be valuable weapons in the fight against cancer and a broad-spectrum multiple checkpoint inhibitor like KULA101 might advance the class of cancer immunotherapies significantly if proven clinically. Additionally, by modifying the tumor microenvironment KULA101 might also prove itself to be a valuable pre-treatment or co-treatment regimen for chimeric antigen receptor therapy (CAR-T) and other adoptive cell immunotherapies,” commented Dr. Marc Lippman, chief medical officer and Deputy Director of the University of Miami’s Sylvester Comprehensive Cancer Center. “Metabolic modulation...

Partikula Announces $5 Million Series A Funding to Develop Novel First-In-Class Mitochondrial Targeted Therapeutics

Davie, Florida – February 2, 2015 – Partikula, LLC (“Partikula”), a preclinical stage biopharmaceutical company, announced today its closing of a Series A financing. 2M Companies led the $5 million round. Partikula will use the proceeds from this financing to support the development of its portfolio of novel mitochondrial-targeting agents, initially focusing on inhibitors of cancer metabolism and survival. Partikula was formed in 2013 by seasoned life science entrepreneur and CEO David Kolb to capitalize on novel chemistries capable of delivering therapeutic agents directly to the mitochondria. “Utilizing our platform chemistries we are able to access a wealth of well studied but difficult to reach targets that control a variety of important cellular functions”, commented Mr. Kolb. Dr. Marc Lippman, Deputy Director of the Sylvester Cancer Center at the University of Miami and the company’s Chief Medical Officer, added, “with its mitochondrial targeting platform, Partikula can now access hard-to-reach targets that control a variety of important cellular mechanisms and pathways including metabolism, apoptosis, fission/fusion, physiological sensing and cell cycle maintenance with applicability across many therapeutic areas beginning with oncology but reaching out across neurology, cardiology, metabolic disease and rare orphan diseases.” Partikula is initially applying its platform technology in the area of oncology. The company has developed a family of metabolic inhibitors including therapeutics that target pyruvate dehydrogenase kinase (PDK) and hexokinase (HK), both essential elements of cellular metabolism pathways that are significantly augmented in many forms of cancer. “By inhibiting cancer metabolism at its core location we hope to have a potent and specific effect against cancer cells while avoiding resistance mechanisms and crosstalk upstream of the mitochondria,”...

Partikula Featured in BioCentury Emerging Company Profiles

Partikula delivering chemotherapeutics into mitochondria of cancer cells Partikula: Mitochondrial delivery By Lev Osherovich Senior Writer Published on Monday, March 17, 2014 Partikula LLC is developing nanoparticles that have size and charge optimized to deliver therapeutic payloads into mitochondria, beginning with two lead programs that aim to disrupt cancer metabolism by using the technology to deliver chemotherapeutic and cytotoxic agents. Mitochondria drive cellular metabolism. The intracellular organelles are particularly active in cancers, which require substantial amounts of energy to grow. However, selectively hitting mitochondrial targets has proven challenging because drugs must cross multiple membranes. Read more at...